Fecal short-chain fatty acids in non-constipated irritable bowel syndrome: a potential clinically relevant stratification factor based on catabotyping analysis

References

• Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterol. 2021;160:99–114 e3. doi:10.1053/j.gastro.2020.04.014.
   PubMed Web of Science ®Google Scholar
• Bellini M, Gambaccini D, Stasi C, Urbano MT, Marchi S, Usai-Satta P. Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol. 2014;20(27):8807–17. doi:10.3748/wjg.v20.i27.8807.
   PubMed Web of Science ®Google Scholar
• Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, Agrawal A, Aziz I, Farmer AD, Eugenicos MP, et al. British society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214–1240. doi:10.1136/gutjnl-2021-324598.
   PubMed Web of Science ®Google Scholar
• Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. The microbiome and irritable bowel syndrome - a review on the pathophysiology current research and future therapy. Front Microbiol. 2019;10:1136. doi:10.3389/fmicb.2019.01870.
   PubMed Web of Science ®Google Scholar
• Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, et al. Microbiota in health and diseases. Signal Transduction And Targeted Therapy. 2022;7:135. doi:10.1038/s41392-022-00974-4.
   PubMed Web of Science ®Google Scholar
• Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28(10):1221–1227. doi:10.1136/gut.28.10.1221.
   PubMed Web of Science ®Google Scholar
• Akhtar M, Chen Y, Ma Z, Zhang X, Shi D, Khan JA, Liu H. Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation. Anim Nutr. 2022;8:350–360. doi:10.1016/j.aninu.2021.11.005.
   PubMedGoogle Scholar
• Martin-Gallausiaux C, Marinelli L, Blottiere HM, Larraufie P, Lapaque N. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;80(1):37–49. doi:10.1017/S0029665120006916.
   PubMed Web of Science ®Google Scholar
• Cong J, Zhou P, Zhang R. Intestinal microbiota-derived short chain fatty acids in host health and disease. Nutrients. 2022;14(9):14. doi:10.3390/nu14091977.
   Web of Science ®Google Scholar
• Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). 2020;11:25. doi:10.3389/fendo.2020.00025.
   PubMed Web of Science ®Google Scholar
• Luo M, Zhuang X, Tian Z, Xiong L. Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21(1):14. doi:10.1186/s12876-020-01577-5.
   PubMed Web of Science ®Google Scholar
• Gargari G, Taverniti V, Gardana C, Cremon C, Canducci F, Pagano I, Barbaro MR, Bellacosa L, Castellazzi AM, Valsecchi C, et al. Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. Environ Microbiol. 2018;20(9):3201–3213. doi:10.1111/1462-2920.14271.
   PubMed Web of Science ®Google Scholar
• Sun Q, Jia Q, Song L, Duan L. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: a systematic review and meta-analysis. Medicine. 2019;98(7):e14513. doi:10.1097/MD.0000000000014513.
   PubMed Web of Science ®Google Scholar
• Fredericks E, Theunissen R, Roux S. Short chain fatty acids and monocarboxylate transporters in irritable bowel syndrome. Turk J Gastroenterol. 2020;31:840–847. doi:10.5152/tjg.2020.19856.
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Lauritano EC, Lupascu A, Petruzzellis C, Novi ML, Roccarina D, Gabrielli M, Serricchio M, Gasbarrini G, Gasbarrini A, et al. Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome. Dig And Liver Dis Supp. 2007;1(1):19–22. doi:10.1016/S1594-5804(08)60006-6.
   Google Scholar
• Lewandowski K, Kaniewska M, Karlowicz K, Rosolowski M, Rydzewska G. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022;17:28–34. doi:10.5114/pg.2021.112681.
   PubMed Web of Science ®Google Scholar
• Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol. 2016;16(1):51. doi:10.1186/s12876-016-0446-z.
   PubMedGoogle Scholar
• Ringel-Kulka T, Choi CH, Temas D, Kim A, Maier DM, Scott K, Galanko JA, Ringel Y. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol. 2015;110:1339–1346. doi:10.1038/ajg.2015.220.
   PubMed Web of Science ®Google Scholar
• Shaikh SD, Sun N, Canakis A, Park WY, Weber HC. Irritable bowel syndrome and the gut microbiome: a comprehensive review. J Clin Med. 2023;12(7):2558. doi:10.3390/jcm12072558.
   PubMed Web of Science ®Google Scholar
• Su Q, Tun HM, Liu Q, Yeoh YK, Mak JWY, Chan FKL, Ng SC. Gut microbiome signatures reflect different subtypes of irritable bowel syndrome. Gut Microbes. 2023;15:2157697. doi:10.1080/19490976.2022.2157697.
   PubMed Web of Science ®Google Scholar
• Jacobs JP, Lagishetty V, Hauer MC, Labus JS, Dong TS, Toma R, Vuyisich M, Naliboff BD, Lackner JM, Gupta A, et al. Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes. Microbiome. 2023;11(1):5. doi:10.1186/s40168-022-01450-5.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32. doi:10.1056/NEJMoa1004409.
   PubMed Web of Science ®Google Scholar
• Vervier K, Moss S, Kumar N, Adoum A, Barne M, Browne H, Kaser A, Kiely CJ, Neville BA, Powell N, et al. Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut. 2022;71(9):1821–1830. doi:10.1136/gutjnl-2021-325177.
   PubMedGoogle Scholar
• Rangel I, Sundin J, Fuentes S, Repsilber D, de Vos WM, Brummer RJ, de Vos WM. The relationship between faecal-associated and mucosal-associated microbiota in irritable bowel syndrome patients and healthy subjects. Aliment Pharmacol Ther. 2015;42:1211–1221. doi:10.1111/apt.13399.
   PubMed Web of Science ®Google Scholar
• Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J, Störsrud S, Le Nevé B, Öhman L, Simrén M, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111–23 e8. doi:10.1053/j.gastro.2016.09.049.
   PubMed Web of Science ®Google Scholar
• Duan R, Zhu S, Wang B, Duan L. Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: a systematic review. Clin Transl Gastroenterol. 2019;10(2):e00012. doi:10.14309/ctg.0000000000000012.
   PubMedGoogle Scholar
• Wang L, Alammar N, Singh R, Nanavati J, Song Y, Chaudhary R, Mullin GE. Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. J Acad Nutr Diet. 2020;120:565–586. doi:10.1016/j.jand.2019.05.015.
   PubMed Web of Science ®Google Scholar
• Shaidullov IF, Sorokina DM, Sitdikov FG, Hermann A, Abdulkhakov SR, Sitdikova GF. Short chain fatty acids and colon motility in a mouse model of irritable bowel syndrome. BMC Gastroenterol. 2021;21(1):37. doi:10.1186/s12876-021-01613-y.
   PubMed Web of Science ®Google Scholar
• Mitsui R, Ono S, Karaki S, Kuwahara A. Neural and non-neural mediation of propionate-induced contractile responses in the rat distal colon. Neurogastroenterol Motil. 2005;17(4):585–594. doi:10.1111/j.1365-2982.2005.00669.x.
   PubMed Web of Science ®Google Scholar
• Reigstad CS, Salmonson CE, Rainey JF 3rd, Szurszewski JH, Linden DR, Sonnenburg JL, Farrugia G, Kashyap PC. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J. 2015;29:1395–1403. doi:10.1096/fj.14-259598.
   PubMed Web of Science ®Google Scholar
• BouSaba J, Zheng T, Dilmaghani S, Johnson S, Chen J, Camilleri M. Effect of rapid colonic transit on stool microbiome and short-chain fatty acids in diarrhoea-predominant irritable bowel syndrome. Gut. 2023;gutjnl-2022–329359. doi:10.1136/gutjnl-2022-329359.
   Web of Science ®Google Scholar
• Jiang W, Wu J, Zhu S, Xin L, Yu C, Shen Z. The role of short chain fatty acids in irritable bowel syndrome. J Neurogastroenterol Motil. 2022;28(4):540–548. doi:10.5056/jnm22093.
   PubMed Web of Science ®Google Scholar
• Connors J, Dawe N, Van Limbergen J. The role of succinate in the Regulation of intestinal inflammation. Nutrients. 2018;11(1):11. doi:10.3390/nu11010025.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamashita R, Kawashima J, Mori H, Kurokawa K, Fukuda S, Gotoh Y, Nakamura K, Hayashi T, Kasahara Y, et al. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. J Gastroenterol. 2022;57(10):748–760. doi:10.1007/s00535-022-01888-2.
   PubMed Web of Science ®Google Scholar
• Ahluwalia B, Iribarren C, Magnusson MK, Sundin J, Clevers E, Savolainen O, Ross AB, Törnblom H, Simrén M, Öhman L, et al. A distinct faecal microbiota and metabolite profile linked to bowel habits in patients with irritable bowel syndrome. Cells. 2021;10(6):10. doi:10.3390/cells10061459.
   Web of Science ®Google Scholar
• Luu M, Pautz S, Kohl V, Singh R, Romero R, Lucas S, Hofmann J, Raifer H, Vachharajani N, Carrascosa LC, et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. Nat Commun. 2019;10(1):760. doi:10.1038/s41467-019-08711-2.
   PubMedGoogle Scholar
• Zhang WX, Zhang Y, Qin G, Li KM, Wei W, Li SY, Yao S-K. Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome. World J Gastroenterol. 2019;25:6416–6429. doi:10.3748/wjg.v25.i43.6416.
   PubMed Web of Science ®Google Scholar
• Sun QH, Liu ZJ, Zhang L, Wei H, Song LJ, Zhu SW, He MB, Duan LP. Sex-based differences in fecal short-chain fatty acid and gut microbiota in irritable bowel syndrome patients. J Dig Dis. 2021;22:246–255. doi:10.1111/1751-2980.12988.
   PubMed Web of Science ®Google Scholar
• Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto J-M, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–180. doi:10.1038/nature09944.
   PubMed Web of Science ®Google Scholar
• Knights D, Ward TL, McKinlay CE, Miller H, Gonzalez A, McDonald D, Knight R. Rethinking “enterotypes”. Cell Host & Microbe. 2014;16:433–437. doi:10.1016/j.chom.2014.09.013.
   PubMed Web of Science ®Google Scholar
• Costea PI, Hildebrand F, Arumugam M, Backhed F, Blaser MJ, Bushman FD, de Vos WM, Ehrlich S, Fraser CM, Hattori M, et al. Enterotypes in the landscape of gut microbial community composition. Nat microbiol. 2018;3:8–16. doi:10.1038/s41564-017-0072-8.
   PubMed Web of Science ®Google Scholar
• Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:512-9, e114–5. doi:10.1111/j.1365-2982.2009.01427.x.
   Web of Science ®Google Scholar
• Wang T, Rijnaarts I, Hermes GDA, de Roos NM, Witteman BJM, de Wit NJW, Govers C, Smidt H, Zoetendal EG. Fecal microbiota signatures are not consistently related to symptom severity in irritable bowel syndrome. Dig Dis Sci. 2022;67:5137–5148. doi:10.1007/s10620-022-07543-3.
   PubMed Web of Science ®Google Scholar
• Kamath PS, Phillips SF, Zinsmeister AR. Short-chain fatty acids stimulate ileal motility in humans. Gastroenterology. 1988;95(6):1496–1502. doi:10.1016/S0016-5085(88)80068-4.
   PubMed Web of Science ®Google Scholar
• Xu D, Wu X, Grabauskas G, Owyang C. Butyrate-induced colonic hypersensitivity is mediated by mitogen-activated protein kinase activation in rat dorsal root ganglia. Gut. 2013;62(10):1466–1474. doi:10.1136/gutjnl-2012-302260.
   PubMed Web of Science ®Google Scholar
• Carco C, Young W, Gearry RB, Talley NJ, McNabb WC, Roy NC. Increasing evidence that irritable bowel syndrome and functional gastrointestinal disorders have a microbial pathogenesis. Front Cell Infect Microbiol. 2020;10:10. doi:10.3389/fcimb.2020.00468.
   PubMed Web of Science ®Google Scholar
• Hurst NR, Kendig DM, Murthy KS, Grider JR. The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon. Neurogastroenterol Motil. 2014;26(11):1586–1596. doi:10.1111/nmo.12425.
   PubMed Web of Science ®Google Scholar
• Eetemadi A, Tagkopoulos I. Methane and fatty acid metabolism pathways are predictive of low-FODMAP diet efficacy for patients with irritable bowel syndrome. Clin Nutr. 2021;40:4414–4421. doi:10.1016/j.clnu.2020.12.041.
   PubMed Web of Science ®Google Scholar
• Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, Versalovic J, Shulman RJ. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther. 2015;42:418–427. doi:10.1111/apt.13286.
   PubMed Web of Science ®Google Scholar
• Quigley EMM, Markinson L, Stevenson A, Treasure FP, Lacy BE. Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57(1):81–93. doi:10.1111/apt.17310.
   PubMed Web of Science ®Google Scholar
• Wang M, Xie X, Zhao S, Ma X, Wang Z, Zhang Y. Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Front Immunol. 2023;14:14. doi:10.3389/fimmu.2023.1136343.
   Web of Science ®Google Scholar
• Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60. doi:10.1186/gb-2011-12-6-r60.
   PubMed Web of Science ®Google Scholar